The GPALPP1 Knockout HT29 Polyclonal Cells product is a CRISPR/Cas9-edited polyclonal cell population derived from the HT29 human colorectal adenocarcinoma epithelial line, featuring targeted gene disruption of GPALPP1. This polyclonal knockout pool contains a diverse mixture of edited alleles, offering a robust, unbiased system for assessing GPALPP1-dependent functions without the limitations of clonal isolates. It is ideally suited for pooled loss-of-function screens and population-level molecular studies.
HT29 cells are an established model of human intestinal epithelium, originally isolated from a primary colorectal adenocarcinoma. They retain the ability to undergo differentiation into mature, polarized enterocyte-like cells when subjected to metabolic stress or butyrate treatment, enabling studies on intestinal barrier function, drug absorption, and colorectal cancer pathology. This well-characterized cellular background provides a physiologically relevant context for investigating RNA processing defects in cancer.
GPALPP1 encodes an uncharacterized RNA-binding protein containing both a G-patch domain, known to mediate helicase interactions, and Lsm domains that facilitate RNA binding and protein oligomerization. These domain features suggest a role in pre-mRNA splicing and mRNA processing, likely through association with the spliceosomal machinery. GPALPP1 is predicted to interact with core spliceosomal snRNPs, the splicing factor PRPF8, and the DHX15 RNA helicase, potentially forming dynamic complexes that influence alternative splicing regulation. The precise upstream signals and downstream mRNA targets of GPALPP1 remain to be defined, though it is expected to modulate a subset of splice events.
Genetic disruption of GPALPP1 in the HT29 colorectal adenocarcinoma model creates a valuable tool for elucidating its function in post-transcriptional gene regulation and its impact on tumor cell phenotypes. Given the pervasive role of splicing dysregulation in oncogenesis and the frequent overexpression of RNA-binding proteins in colorectal cancers, this knockout model enables systematic interrogation of how GPALPP1 loss reshapes splicing landscapes and gene expression programs, and how these changes translate into altered proliferation, migration, and drug sensitivity. It may highlight spliceosome-related vulnerabilities in colorectal cancer.
Routine experimental applications include western blotting and RT-qPCR to confirm GPALPP1 protein and transcript reduction, RNA sequencing for comprehensive splicing and expression profiling, and cell-based assays assessing proliferation, migratory capacity, and chemotherapeutic response. This product supports mechanistic dissection of GPALPP1??s role in mRNA metabolism and its potential as a colorectal cancer therapeutic target. For further information or to explore custom uses, please reach out to Ascent Research.
